GSK GLP-1 albiglutide faces 3-month FDA delay
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's hopes of having its experimental glucagon-like peptide-1 (GLP-1) receptor agonist albiglutide on the US market as a once-weekly treatment for adults with type 2 diabetes by 14 January 2014 were dashed after the FDA said it needed at least three more months to review the biologics license application (BLA).